Less vs more frequent follow-up after early breast cancer
Part of Cancer, Skin clinical trials.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early breast cancer that has been fully removed with clear surgical margins
- Your cancer is considered intermediate- to high-risk (for example, larger tumor, lymph node spread, higher grade, or plan for chemo)
- You finished the main cancer treatment (surgery, radiation, and/or chemo—whichever was last) between 4 weeks and 24 months ago
- There is no current sign that the cancer has spread to distant organs
- You can provide stored breast tumor samples (from a prior biopsy or surgery tissue block/slides) for testing
- You can attend scheduled study visits and follow required tests; you’re age 18–75 and your overall health score is 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study tests whether some patients who finished curative breast cancer treatment can safely have fewer follow-up appointments and scans. Researchers want to see if less frequent monitoring is safe for patients without any signs of cancer returning.
This study looks at a patient-led follow-up approach after early breast cancer treatment, where you may have more control and flexibility instead of routine hospital visits, while still on hormone therapy.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.